Is Geriatric-Focused INGREZZA Data Quietly Reframing Neurocrine Biosciences' Neurology Leadership Narrative (NBIX)? [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
dyskinesia in older adults in long-term care, alongside new KINECT-PRO post-hoc data on INGREZZA at the PALTC26 conference in Anaheim. The combination of aging-focused guidance and patient-reported outcome data highlights Neurocrine's push to deepen INGREZZA's clinical relevance in a high-need geriatric population. We'll now explore how these geriatric-focused INGREZZA findings might influence Neurocrine Biosciences' investment narrative, particularly its neurology leadership thesis. AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. Neurocrine Biosciences Investment Narrative Recap To own Neurocrine Biosciences, you need to believe INGREZZA and CRENESSITY can support durable growth while the CNS pipeline gradually broadens the revenue base. The new geriatric INGREZZA data and TD care recommendations help reinforce th
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care SettingsPR Newswire
- Biocom Appoints New Members to Its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations OfficerPR Newswire
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/17/26 - Form 3
- 3/5/26 - Form 4
- NBIX's page on the SEC website